Coherus Oncology (CHRS) Cash & Equivalents (2013 - 2026)
Coherus Oncology (CHRS) reported Cash & Equivalents of $82.92 million for Q2 2026, down 61.8% from $216.89 million a year earlier and down 28.0% from the prior quarter.
Coherus Oncology (CHRS) Cash & Equivalents (2013 - 2026) Analysis & Trends
At the end of FY2025, Coherus Oncology posted Cash & Equivalents of $88.88 million, down 29.5% from FY2024.
- Cash & Equivalents has a five-year compound annual growth rate of -30.3% (FY2020 to FY2025).
- By year, Cash & Equivalents came in at $125.99 million in FY2024 (+22.4%), $102.89 million in FY2023 (+61.9%), $63.55 million in FY2022 (-84.8%) and $417.2 million in FY2021 (-22.9%).
- The Q2 2026 figure ranks as the lowest quarterly Cash & Equivalents since Q1 2025.
- Year over year, Cash & Equivalents gained in five of the last eight quarters, with an average decline of 4.2%.
- The high point for year-over-year Cash & Equivalents in five years was Q2 2024 (growth of 118.4%); the low point was Q1 2023 (a decline of 95.0%).
- Per Business Quant data, the three quarters before Q2 2026 came in at $115.24 million (Q1 2026), $88.88 million (Q4 2025) and $103.35 million (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash & Equiv. (Qtr) |
|---|---|---|---|---|---|
| 1 | Eli Lilly | 1,122.91 Bn | 1,091.50 Bn | 19.71 Bn | 8.95 Bn |
| 2 | Johnson & Johnson | 615.09 Bn | 533.62 Bn | 17.26 Bn | 20.42 Bn |
| 3 | AbbVie | 504.75 Bn | 477.86 Bn | 12.70 Bn | 6.57 Bn |
| 4 | Merck | 360.18 Bn | 314.55 Bn | 12.21 Bn | 6.85 Bn |
| 5 | Novartis Ag | 292.05 Bn | 256.04 Bn | 11.24 Bn | 7.62 Bn |
| 6 | Astrazeneca | 256.09 Bn | 229.78 Bn | 12.86 Bn | 4.90 Bn |
| 7 | Amgen | 233.63 Bn | 189.02 Bn | 7.24 Bn | 13.99 Bn |
| 8 | Gilead Sciences | 194.49 Bn | 168.69 Bn | 6.22 Bn | 3.18 Bn |
| 9 | Pfizer | 168.35 Bn | 114.99 Bn | 10.94 Bn | 976.00 Mn |
| 10 | Coherus Oncology | 155.59 Mn | -480.55 Mn | 10.07 Mn | 82.92 Mn |
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 82.92 Mn |
| Mar 31, 2026 | 115.24 Mn |
| Dec 31, 2025 | 88.88 Mn |
| Sep 30, 2025 | 103.35 Mn |
| Jun 30, 2025 | 216.89 Mn |
| Mar 31, 2025 | 82.41 Mn |
| Dec 31, 2024 | 125.99 Mn |
| Sep 30, 2024 | 97.69 Mn |
| Jun 30, 2024 | 159.24 Mn |
| Mar 31, 2024 | 259.78 Mn |
| Dec 31, 2023 | 102.89 Mn |
| Sep 30, 2023 | 80.26 Mn |
| Jun 30, 2023 | 72.92 Mn |
| Mar 31, 2023 | 16.15 Mn |
| Dec 31, 2022 | 63.55 Mn |
| Sep 30, 2022 | 286.81 Mn |
| Jun 30, 2022 | 275.48 Mn |
| Mar 31, 2022 | 325.68 Mn |
| Dec 31, 2021 | 417.20 Mn |
| Sep 30, 2021 | 360.54 Mn |
Coherus Oncology Cash & Equivalents API
Pull this series into your own models, spreadsheets and apps with the Business Quant
Historical Metrics API. The request below matches the chart above — change the
frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.
https://data.businessquant.com/historic?slug=cash-and-equivalents&ticker=CHRS&period=max&api_key=YOUR_API_KEY
import requests
url = "https://data.businessquant.com/historic"
params = {"slug": "cash-and-equivalents", "ticker": "CHRS", "period": "max", "api_key": "YOUR_API_KEY"}
data = requests.get(url, params=params).json()
const res = await fetch("https://data.businessquant.com/historic?slug=cash-and-equivalents&ticker=CHRS&period=max&api_key=YOUR_API_KEY");
const data = await res.json();